Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The current
study assessed in vivo the effect of insulin on triglyceride-rich
lipoprotein (TRL) production by rat liver. Hepatic triglyceride and
apolipoprotein B (apoB) production were measured in anesthetized,
fasted rats injected intravenously with Triton WR-1339 (400 mg/kg).
After intravascular catabolism was blocked by detergent treatment,
glucose (500 mg/kg) was injected to elicit insulin secretion, and serum
triglyceride and apoB accumulation were monitored over the next 3 h. In glucose-injected rats, triglyceride secretion averaged 22.5 ± 2.1 µg · ml1 · min
1,
which was significantly less by 30% than that observed in
saline-injected rats, which averaged 32.1 ± 1.4 µg · ml
1 · min
1. ApoB
secretion was also significantly reduced by 66% in glucose-injected rats. ApoB immunoblotting indicated that both B100 and B48 production were significantly reduced after glucose injection. Results support the
conclusion that insulin acts in vivo to suppress hepatic very low
density lipoprotein (VLDL) triglyceride and apoB secretion and
strengthen the concept of a regulatory role for insulin in VLDL
metabolism postprandially.
lipoprotein secretion by liver; very low density lipoprotein; Triton WR-1339 treatment; in vivo apolipoprotein B production
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
INSULIN PLAYS A KEY REGULATORY ROLE in the synthesis and secretion of triglyceride-rich lipoproteins (TRL) by liver (reviewed in Ref. 45). High levels of insulin inhibit secretion and release of very low density lipoproteins (VLDL) by rat hepatocytes (2, 10, 30, 38, 43), by Hep G2 cells (6, 33), and by rat liver in perfusion (47). In humans, acute hyperinsulinemia also inhibits VLDL and triglyceride production (20-23, 25) by suppressing the production of large, VLDL1 B100 particles (23, 25). In rat hepatocytes, the insulin effect is receptor mediated (31) and is dependent on the activation (42) and translocation of phosphatidylinositide 3-kinase (PI 3-kinase) to an intracellular compartment involved in VLDL biogenesis (32). Downstream consequences of this signaling cascade result in increased intracellular apolipoprotein B (apoB) degradation and decreased apoB synthesis (43).
Most studies of insulin action on VLDL secretion have been performed in cell culture systems in which insulin is added to medium, and effects on lipoproteins and apoB are evaluated at various times thereafter (30, 33, 43). Cell culture systems, however, cannot fully reflect the events present in intact animals. Important features that may be lost include the dynamic interplay of regulatory and counterregulatory factors that change relative to insulin and are important in the transition from fed to fasted states, including changes in free fatty acids (FFAs). In vivo studies in humans are even more complicated, as lipoprotein catabolism cannot be blocked effectively while assessing hepatic lipoprotein production rates by non-steady-state or steady-state isotope enrichment methods.
In the current study, we were interested in determining whether the ability of insulin to suppress hepatic VLDL production could be documented in vivo. Our experimental approach was to follow hepatic triglyceride and apoB production rates after bolus injection of glucose to elicit insulin secretion while simultaneously preventing lipoprotein catabolism by using the nonionic detergent Triton WR-1339 (3, 13, 15, 28, 29). Fasted rats were employed to minimize the contribution by the intestine to apoB and triglyceride production rates. As shown in the current study, bolus glucose injection resulted in the rapid release of insulin in the circulation, which led to the significant suppression of hepatic triglyceride and apoB production. This result supports the concept that in vivo insulin action limits rather than stimulates hepatic secretion of VLDL. We conclude that insulin acts in vivo and in vitro to regulate VLDL and apoB secretion by liver.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Animals and surgery. The protocol used in this study was approved by the University Committee on Animal Resources, University of Rochester. Male Sprague-Dawley [Crl:CD (SD) BR] rats weighing 200-300 g were housed on a 12:12-h light-dark cycle with free access to standard rodent chow and drinking water for at least 7 days before experimentation.
Primary rat hepatocyte experiments. Collagenase perfusions of rat liver were performed to prepare hepatocytes between 0800 and 1000, and viable hepatocytes were isolated using Percoll (Pharmacia Fine Chemicals, Piscataway, NJ; see Ref. 41). Hepatocytes were centrifuged for 2 min at 50 g and were resuspended in Waymouth's medium MB752/l containing 0.2% (wt/vol) BSA, hereafter referred to as Waymouth's medium. Hepatocytes were seeded on sterile 60-mm culture dishes precoated with rat tail collagen, and dishes were then incubated at 37°C in an atmosphere of 95% air-5% CO2. For insulin dose-response studies, hepatocytes were incubated for 14-16 h in Waymouth's medium containing various concentrations of porcine pancreas insulin (Sigma Chemical, St. Louis, MO). In several experiments, in addition to insulin, other serum factors were added to medium, including dexamethasone (1 µM), glucagon (100 nM), or oleic acid/BSA complexes (0.75 mM). Oleic acid/BSA complexes were prepared at a molar ratio of fatty acid to albumin of approximately four to one, as previously described (49). At the end of the incubation period, media were collected, cells were washed three times in Hanks' balanced salt solution, and cell lysates were prepared in 0.5% (vol/vol) Triton X-100, as previously described (43). Cellular protein of each dish was measured by a modification of the Lowry procedure (26).
In vivo experiments. Rats were fasted for 16-18 h the night before experiments were carried out. Rats were anesthetized with ketamine (80 mg/kg) and xylazine (10 mg/kg) and were fitted with carotid (polyethylene 10; Clay Adams) and jugular (22 gauge; Intracath) catheters (Becton-Dickinson, Sandy, UT). Anesthesia was maintained throughout the experimental period. The arterial line was connected to an infusion pump, and saline was infused at a rate of 1.5 ml/h. The venous line was flushed with a small volume of heparinized saline (20 U/ml) and was stoppered with a Luer-lock injection site adapter (Baxter Healthcare, Deerfield, IL). Catheters were secured using several silk sutures (5-0), and rats were allowed 30 min to acclimatize. Tyloxapol (Triton WR-1339) diluted in saline (300 mg/ml) and warmed to 37°C was slowly injected (1-3 min) via the jugular line (400 mg/kg body wt). Immediately thereafter, glucose dissolved in saline [45% (wt/vol)] or an equivalent volume of saline alone was injected intravenously (500 mg/kg body wt). Blood was sampled at 0, 30, 60, 90, 120, 150, and 180 min thereafter and was collected in microfuge tubes. Blood was allowed to clot, and serum was prepared by centrifugation. In control studies using intravenous L-arginine injection, the dosage of arginine used was 2.1 mmol/kg to elicit insulin secretion (9). Blood was collected at 0 and 60 min after arginine injection, and serum was prepared.
Experimental procedures. Serum glucose was measured by a colorimetric assay employing glucose oxidase (Sigma Diagnostics). Serum cholesterol was quantitated using a cholesterol oxidase method (1), and serum triglycerides were measured by assay of glycerol released after lipase treatment (27). Serum FFAs were determined by a kit (Wako FFA kit, Englewood, NJ). Serum insulin was measured by RIA using a commercial kit (Linco Research, St. Charles, MO) and modified rat insulin standards. Rat insulin standards were reconstituted in buffer containing 0.8% (vol/vol) Triton WR-1339. Cell and media apoB concentrations were assayed by monoclonal immunoassay (40), and results were normalized to protein content per dish. For apoB immunoblotting, 25 µl of freshly prepared serum were mixed with 225 µl of 0.1 M Tris · HCl buffer, pH 7.0, containing 10% (wt/vol) SDS, 100 mM dithiothreitol, 10% (vol/vol) 2-mercaptoethanol, and 20% (vol/vol) glycerol. Samples were mixed thoroughly, heated to 100°C for 15 min, and centrifuged to remove nonsolubilized material. Samples and authentic rat B100 and rat B48 standards were loaded on Acrylaide/acrylamide gradient gels, and proteins were separated by SDS-PAGE (46). To control for potential variability in gel separation and in electrophoretic transfer, timed serum samples from saline-injected rats were electrophoresed on the same slab gel as those from glucose-injected rats. Separated proteins were electrophoretically transferred to polyvinylidene difluoride (PVDF) membranes (46), and nonspecific binding sites were blocked by overnight incubation at 4°C in 0.1 M Tris · HCl buffer, pH 7.0, containing 0.05% (wt/vol) Tween 20 and 5% (wt/vol) milk. Membranes were incubated with rabbit anti-rat apoB in blocking buffer overnight at 4°C, and then membranes were washed three times in 0.1 M Tris · HCl buffer, pH 7.0, containing 0.05% (vol/vol) Tween 20 (wash buffer). Antibody binding was detected by final incubation for 4 h at room temperature with 125I-labeled goat anti-rabbit IgG (Amersham Pharmacia Biotech) in blocking buffer. After thorough rinsing of membranes in wash buffer, membranes were air-dried, and labeled antibody bound was visualized by PhosphorImager detection.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Inhibition of apoB secretion by insulin in hepatocytes derived from
fasted rats.
Previous studies of insulin effects on apoB secretion in primary
hepatocyte cultures used cells derived from fed rats (2, 38, 41,
43, 44). Our in vivo strategy necessitated the use of fasted
rats to minimize the intestinal contribution to lipoprotein production;
therefore, we first evaluated the effect of fasting on the ability of
insulin to inhibit apoB secretion. This evaluation involved the
comparison of insulin dose effects on apoB secretion by hepatocytes
derived from fed and fasted rats (Fig.
1). In hepatocytes derived from fasted
rats, a slightly higher level of inhibition of apoB secretion was
attained, averaging 46 ± 3.6% (mean ± SE;
n = 11 livers). The comparable maximum inhibition of
apoB secretion elicited by insulin in hepatocytes derived from fed rats
averaged 40 ± 2.5% (n = 14 livers). The initial
medium insulin concentration at which 50% of the maximum inhibitory
effect on apoB secretion is achieved was 0.9 nM in hepatocytes derived from fasted rats and 1.7 nM in hepatocytes derived from fed rats. These
values are similar to that previously reported of 1 nM insulin observed
in hepatocytes derived from lean Zucker rats (44).
|
Effects of dexamethasone, oleic acid, and glucagon on hepatocyte
apoB secretion.
To further support the use of our in vivo strategy, we evaluated the
suppressive effect of insulin on apoB secretion by hepatocytes derived
from fasted rats in coincubation studies employing a number of
effectors known to be physiologically important in fasting animals but
not routinely considered in rat hepatocyte cell culture experiments.
These factors included dexamethasone, oleic acid, and glucagon (Fig.
2). The inhibitory effect of insulin on
apoB secretion by primary cultures of hepatocytes derived from fasted rats is preserved even when insulin is coincubated with 1 µM
dexamethasone, 0.75 mM oleic acid, or 100 nM glucagon.
|
Glucose dosage effects on serum glucose levels.
After the use of the fasted rat model was validated, the optimal
concentration of glucose for bolus injections was determined. To avoid
possible effects of sustained hyperglycemia, the dosage of glucose was
determined that allowed for the return of serum glucose to preinjection
values. Rats were fasted for 16-18 h, after which they were
injected intravenously with Triton WR-1339 detergent. Three groups of
rats were then injected (3 rats/group) with glucose at dosages of 500, 1,000, or 2,000 mg/kg body wt. The immediate serum glucose
concentration after injection was calculated by dividing the glucose
dosage by the blood volume, which was assumed to be 5% of the body
weight, and this value was plotted as the peak glucose concentration at
1 min. Serum glucose values at 30 min were dependent on the dosage of
glucose injected (Fig. 3). The highest
serum glucose concentration at 30 min occurred after injection of 2,000 mg/kg, whereas the lowest serum glucose concentration occurred after
injection of 500 mg/kg. The decline in glucose toward fasting levels
was prolonged in groups receiving either 1,000 or 2,000 mg/kg glucose.
In the group of rats injected with 500 mg/kg glucose, serum glucose
returned to baseline levels shortly after 1 h. This latter dose of
500 mg glucose/kg body wt was chosen for bolus injection in subsequent experiments.
|
Glucose-stimulated insulin secretion.
To document that insulin was indeed secreted in response to glucose
injection, serum insulin was assayed (Fig.
4). In glucose-injected rats, serum
insulin rose fourfold ~1 min after glucose injection and fell rapidly
to fasting levels by 1 h after injection. Saline-injected, control
rats maintained fasting insulin levels (data not shown). The acute,
incremental rise in insulin concentration between 0 and 5 min in
response to glucose injection is similar to that observed in fasted
rats upon initiation of a hyperglycemic clamp (48).
|
Effect of glucose-stimulated insulin secretion on hepatic
triglyceride production.
After injection of Triton WR-1339, both hepatic and peripheral
clearance of TRL are blocked (3, 13-15, 28, 29).
Under these conditions, triglyceride accumulates at a rate equivalent to its production rate. In fasted rats, the majority of the
triglyceride that accumulates in plasma originates in the liver. Both
glucose-injected and saline-injected rats demonstrated a linear
accumulation of serum triglycerides over the time course studied (Fig.
5A). Triglyceride secretion
rates over 3 h averaged (n = 9) 32.1 ± 1.4 (SD) µg
triglyceride · ml1 · min
1
in saline-injected rats. The triglyceride secretion rate in
glucose-injected rats was significantly less (P < 0.002) and averaged (n = 9) 22.5 ± 2.1 (SD)
µg · ml
1 · min
1. Hence,
triglyceride accumulation in serum over the 3-h time course was reduced
by 30% after glucose injection vs. saline injection. These results
indicate that hepatic triglyceride production is significantly
suppressed after glucose-stimulated insulin secretion. In control
studies, L-arginine (2.1 mmol/kg) was injected
intravenously to elicit insulin secretion, and serum glucose and
triglyceride were measured 0 and 60 min after injection. Serum glucose
averaged (n = 3) 11.5 ± 0.39 (SD) mM at 0 min and
13.1 ± 0.78 mM at 60 min in saline-injected rats. Serum glucose
results were similar in arginine-injected rats and averaged
(n = 3) 12.1 ± 1.17 (SD) mM at 0 min and
13.4 ± 0.33 mM at 60 min. Initial serum triglycerides (0 min) in
saline-injected and arginine-injected rats were comparable, averaging
(n = 3) 0.98 ± 0.15 (SD) and 0.94 ± 0.28 mM, respectively. At 60 min, serum triglyceride production was
significantly lower by 19% (P < 0.02) in
arginine-injected vs. saline-injected rats, averaging
(n = 3) 3.14 ± 0.25 vs. 3.88 ± 0.11 (SD)
mM, respectively. These results indicate that arginine injection
significantly suppressed triglyceride production by 60 min without
major changes in serum glucose.
|
|
Effect of glucose-stimulated insulin secretion on apoB production
rates.
Because each lipoprotein particle contains a single apoB molecule
(11), VLDL particle production rates can be estimated by
measuring the accumulation of apoB after WR-1339 injection (Fig.
7; see Ref. 16). In saline-injected rats,
the average apoB production rate
(µg · ml1 · h
1) was
(n = 6) 140 ± 39.0 vs. 46 ± 11.8 observed
in glucose-injected rats. These results indicate that hepatic apoB
production is significantly reduced by glucose-stimulated insulin
secretion (P < 0.03). Overall, apoB secretion was
reduced by an average of 66% in glucose-injected rats compared with
saline-injected rats. In control experiments using arginine
injection, apoB production rates
(µg · ml
1 · h
1) at 60 min
were significantly reduced by 47% (P < 0.01) compared with saline injection, averaging (n = 3) 170 ± 18 vs. 91 ± 26 µg · ml
1 · h
1
(n = 3).
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Results from the current in vivo study support previous in vitro experiments demonstrating that insulin inhibits the hepatic secretion of VLDL and apoB (2, 10, 30, 38, 43). Considering that there is one molecule of apoB per lipoprotein particle (11), the decreased production of total apoB, B100, and B48 that we observed supports the conclusion that insulin reduced the hepatic secretion of VLDL particles. Although the liver is the major site of B100 synthesis in the rat, both liver and intestine are able to synthesize and secrete B48 (17, 37) due to expression of the apoB mRNA editing enzyme APOBEC-1 in these tissues (7). The use of fasted rats in the current study, however, minimizes the intestinal contribution of B48 and associated triglyceride-enriched particles.
A short burst of insulin secretion had a suppressive effect on lipoprotein production for 3 h after acute hyperinsulinemia subsided. It is possible that the initial release of insulin by the pancreas via the portal vein, and substantial clearance of insulin by liver during first passage, produces a "priming" effect. This "signal" to liver dictates the retention of hepatic triglyceride destined for secretion during intestinal lipid absorption, with triglyceride levels maximizing ~3-4 h after ingestion of food. We have shown previously that only 5 min of insulin exposure leads to the translocation of cytosolic PI 3-kinase to the rough endoplasmic reticulum (RER), a location where VLDL assembly takes place (32). We speculate that translocated PI 3-kinase may be retained on RER membranes until enzyme activity subsides and dislocation of the enzyme occurs. PI 3-kinase lipid products accumulate in primary hepatocytes over 60 min after a transient 5-min exposure to insulin (data not shown). Hence, downstream effects of PI 3-kinase activation are likely to be maintained as long as phospholipid products are present in membranes. These data suggest that a sustained insulin signal may not be required to observe the inhibitory effect on triglyceride and apoB secretion.
Because apoB suppression is greater than triglyceride suppression after glucose injection, the net effect is to increase the triglyceride-to-apoB ratio and increase particle size. Further studies need to be performed, including secretory kinetics of B48 and B100 relative to triglyceride, to clearly make this point, since, although there was suppression of both B48 and B100, accurate quantitation was not possible. In addition, earlier time points reflect the smaller apoB-containing remnants present in fasting compared with longer time points that reflect larger, nascent secretory particles. We have therefore been circumspect about drawing conclusions related to changes in particle composition after glucose injection.
In the current study, serum cholesterol levels remained unchanged over the 3-h time period. Because cholesterol in rats is transported primarily in high-density lipoprotein (HDL) and because HDL has a relatively long half-life in serum (39), our results suggest that neither glucose injection nor Triton WR-1339 treatment had a major effect on HDL cholesterol metabolism. However, because the fractional catabolic rate of HDL and its associated apolipoproteins is long compared with the time course studied, no definitive conclusions should be drawn with respect to glucose-stimulated insulin secretion on overall HDL metabolism in detergent-treated rats.
As demonstrated in the current study, time course changes in serum FFAs in glucose- and saline-injected rats were similar. Because Triton WR-1339 suppresses intravascular lipolysis, the release of FFAs derived from TRL lipolysis would be minimal. However, in fasted rats, insulin secretion should inhibit adipose tissue lipolysis. Hence, a decline in serum FFAs might be anticipated due to a combination of tissue uptake of FFAs and reduced entry of FFAs into plasma. As recently shown in fasted rats, plasma FFAs showed a dramatic decline within 15 min of initiating hyperglycemic clamp conditions (48). The major difference between the two studies is that, during the hyperglycemic clamp, insulin levels remained significantly elevated compared with fasting levels, whereas, in the current study, serum insulin levels peaked within minutes of glucose injection but rapidly returned to fasting levels. It is therefore possible that a single pulse of insulin elicited by bolus glucose injection was not able to prevent adipose tissue lipolysis present in the fasting state. Alternatively, because FFAs were unchanged in both glucose- and saline-injected rats and both groups were treated with Triton WR-1339, detergent treatment itself may have had an effect on either FFA release or FFA uptake.
Control studies using primary hepatocytes were performed to validate the use of fasted rats for in vivo studies. These experiments were done because our previous studies of insulin action were conducted in hepatocytes derived from fed rats (2, 12, 32, 41, 43, 44), and the current study necessitated the use of fasted rats to minimize the intestinal contribution to lipoprotein production. In hepatocytes derived from fasted rats, the ability of insulin to inhibit apoB secretion was accentuated compared with hepatocytes derived from fed rats, and this is consistent with increased insulin receptor signaling observed during fasting (35). We also performed experiments to test conditions that may alter VLDL-apoB secretion in the presence of insulin. Studies by Wang et al. (51, 52) indicate that dexamethasone stimulates VLDL apoB secretion. Dexamethasone did not affect apoB secretion in our studies, which employed hepatocytes derived from fasted rats and medium containing basal concentrations of insulin (0.1 nM). Moreover, the inhibitory effect of 100 nM insulin in the presence of dexamethasone was not altered. Fatty acids, specifically 0.75 mM oleic acid, also did not affect apoB secretion in the presence of basal or high levels of insulin, nor did the presence of oleic acid affect the maximum inhibition of apoB secretion attained in medium containing 100 nM insulin. These studies using primary cultures contrast to studies in transformed cells lines (e.g., Hep G2) where fatty acids stimulate the secretion of B100 (8). As we have reported previously (2), glucagon inhibits apoB secretion by rat hepatocytes. The current results demonstrate that this is also true in hepatocytes derived from fasted rats. Importantly, however, is the finding that the maximum inhibition of apoB secretion by insulin is not altered by coincubation with glucagon.
Previous studies have shown that intravenous glucose injection in 4-h-fasted rats results in an almost immediate 5-fold increase in plasma glucose and a 10-fold increase in plasma insulin followed by a sustained two times increase in plasma norepinephrine (NE) 60 min after injection (18). Because NE has been shown to decrease triglyceride and apoB production by perfused liver (54), it is possible that NE released after intravenous glucose might be responsible. Four lines of evidence support that it is insulin release and not NE release that is responsible for the suppression of triglyceride and apoB production. First, in control studies, intravenous arginine injection significantly inhibits triglyceride and apoB production without a major change in blood glucose. Because elevated blood glucose is the major effector for stimulation of NE release, it is unlikely that NE would be released after arginine injection. Second, levels of plasma NE produced after glucose injection are relatively modest, rising from 250 pg/ml (1.5 nM) to ~500 pg/ml (3 nM; see Ref. 18). The liver perfusion studies of Yamauchi et al. (54) involved high levels of pulsatile NE given at 10-min intervals over the course of 2 h of perfusion at a level in the perfusate of 1 µM. These concentrations represent a 300-fold greater concentration than that produced in vivo after bolus glucose injection. Third, the intravenous glucose dose used in current studies (500 mg/kg) did not lead to an increase in plasma NE in previous studies (19). Fourth, although NE was shown to inhibit B48 secretion by liver, Yamauchi et al. (54) failed to demonstrate a significant effect on B100 secretion. These results differ from the current study showing effects on both B100 and B48.
The role of insulin in the regulation of VLDL secretion is complex. Acute hyperinsulinemia inhibits the production of VLDL triglyceride (2, 10, 30, 38) and apoB (30, 38, 43) by rat hepatocytes and apoB by perfused rat livers (47). The current study demonstrates that the suppressive effect of insulin on VLDL apoB can be demonstrated in vivo. In humans, insulin acutely inhibits the hepatic production of VLDL triglyceride (20, 22-24, 36, 50) and apoB (20, 23-25), and the effect is independent of FFA availability (23). We suggest that the inhibition of hepatic VLDL apoB secretion by insulin prevents the secretion of TRL particles by the liver that would compete with the clearance of intestinal TRL. By inhibiting hepatic VLDL release, intestinal TRL are allowed to be rapidly cleared from the circulation during the postprandial period. The suppression of hepatic TRL secretion also allows hepatic triglyceride stores to expand, and, when insulin levels fall during the postabsorptive period, hepatically stored triglyceride is available to be assembled with apoB to form VLDL for secretion. By regulating hepatic VLDL secretion during the postprandial period, insulin allows for a smooth transition from the fasting state to the fed state in terms of serum triglyceride response. This regulatory pathway may prevent exaggerated hypertriglyceridemia after feeding that might occur if both intestinal and hepatic TRLs were secreted simultaneously and competed for common clearance pathways.
Resistance to insulin-stimulated glucose uptake is a prevalent condition in the human population that is frequently associated with hypertriglyceridemia (reviewed in Ref. 34). The compensatory rise in plasma insulin necessary to normalize blood glucose leads to the enhanced secretion of hepatic VLDL triglyceride and ultimately hypertriglyceridemia. The mechanism for the enhanced secretion of hepatic VLDL in insulin resistance states remains controversial. The mechanism, however, is unlikely to be an exaggerated insulin effect and is more likely to be the result of failure of insulin action. As shown in the current study and in numerous reports, insulin action suppresses rather than stimulates the secretion of hepatic VLDL. Consistent with this concept is the finding that insulin fails to regulate the secretion of VLDL triglyceride (4, 53) and apoB (4, 44, 53) in hepatocytes derived from insulin-resistant rats. The inability of insulin to effectively inhibit the secretion of VLDL apoB has also been demonstrated in patients with type 2 diabetes (24) and in obese women (20). In well-controlled type 2 diabetes patients, however, acute hyperinsulinemia persists in its ability to suppress the hepatic secretion of VLDL apoB (5).
In conclusion, insulin acts in vivo to suppress hepatic VLDL triglyceride and apoB secretion, and these results strengthen the concept of a regulatory role for insulin in VLDL metabolism postprandially.
![]() |
ACKNOWLEDGEMENTS |
---|
This work was supported by research grants from the American Diabetes Association (J. D. Sparks) and by National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-50376 (J. D. Sparks).
![]() |
FOOTNOTES |
---|
* D. V. Chirieac and L. R. Chirieac contributed equally to this work.
Address for reprint requests and other correspondence: J. D. Sparks, Dept. of Pathology and Laboratory Medicine, Univ. of Rochester School of Medicine and Dentistry, Box 626, 601 Elmwood Ave., Rochester, NY 14642 (E-mail: Janet_Sparks{at}URMC.Rochester.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 2 March 2000; accepted in final form 15 June 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Allain, CA,
Poon LS,
Chan CSG,
Richmond W,
and
Fu PC.
Enzymatic determination of total serum cholesterol.
Clin Chem
20:
470-475,
1974
2.
Bjornsson, OG,
Duerden JM,
Bartlett SM,
Sparks JD,
Sparks CE,
and
Gibbons GF.
The role of pancreatic hormones in the regulation of lipid storage, oxidation and secretion in primary cultures of rat hepatocytes. Short- and long-term effects.
Biochem J
281:
381-386,
1992[ISI][Medline].
3.
Borensztajn, J,
Rone MS,
and
Kotlar TJ.
The inhibition in vivo of lipoprotein lipase (clearing-factor lipase) activity by triton WR-1339.
Biochem J
156:
539-543,
1976[ISI][Medline].
4.
Bourgeois, CS,
Wiggins D,
Hems R,
and
Gibbons GF.
VLDL output by hepatocytes from obese Zucker rats is resistant to the inhibitory effect of insulin.
Am J Physiol Endocrinol Metab
269:
E208-E215,
1995
5.
Cummings, MH,
Watts GF,
Umpleby AM,
Hennessy TR,
Kelly JM,
Jackson NC,
and
Sonksen PH.
Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM.
Diabetes
44:
1059-1065,
1995[Abstract].
6.
Dashti, N,
Williams DL,
and
Alaupovic P.
Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells.
J Lipid Res
30:
1365-1373,
1989[Abstract].
7.
Davidson, NO,
Innerarity TL,
Scott J,
Smtih H,
Driscoll DM,
Teng B,
and
Chan L.
Proposed nomenclature for the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme: APOBEC-1.
RNA
1:
3,
1995[ISI][Medline].
8.
Dixon, JL,
and
Ginsberg HN.
Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells.
J Lipid Res
34:
167-179,
1993[Abstract].
9.
Dobbins, RL,
Chester MW,
Stevenson BE,
Daniels MB,
Stein DT,
and
McGarry JD.
A fatty acid-dependent step is critically important for both glucose- and non-glucose-stimulated insulin secretion.
J Clin Invest
101:
2370-2376,
1998
10.
Durrington, PN,
Newton RS,
Weinstein DB,
and
Steinberg D.
Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes.
J Clin Invest
70:
63-73,
1982[ISI][Medline].
11.
Elovson, J,
Chatterton JE,
Bell GT,
Schumaker VN,
Reuben MA,
Puppione DL,
Reeve JR, Jr.,
and
Young NL.
Plasma very low density lipoproteins contain a single molecule of apolipoprotein B.
J Lipid Res
29:
1461-1473,
1988[Abstract].
12.
Gibbons, GF,
Bartlett SM,
Sparks CE,
and
Sparks JD.
Extracellular fatty acids are not utilized directly for the synthesis of very-low-density lipoprotein in primary cultures of rat hepatocytes.
Biochem J
287:
749-753,
1992[ISI][Medline].
13.
Groot, PHE,
DeBoer BCJ,
Haddenman E,
Houtsmuller UMT,
and
Hulsmann WC.
Effect of dietary fat composition on the metabolism of triacylglycerol-rich plasma lipoproteins in the postprandial phase in meal-fed rats.
J Lipid Res
29:
541-551,
1988[Abstract].
14.
Ishikawa, T,
and
Fidge N.
Changes in the concentration of plasma lipoproteins and apoproteins following the administration of Triton WR 1339 to rats.
J Lipid Res
20:
254-264,
1979[Abstract].
15.
Kalopissis, AS,
Griglio S,
Malewiak M,
and
Rozen R.
Effect of a high-fat diet on rat very low density lipoprotein secretion.
Biochim Biophys Acta
620:
111-119,
1980[ISI][Medline].
16.
Kasim, SE,
Elovson J,
Khilnani S,
Almario RU,
and
Jen K-LC.
Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rats.
Atherosclerosis
104:
147-152,
1993[ISI][Medline].
17.
Krishnaiah, KV,
Walker LF,
Borensztajn J,
Schonfeld G,
and
Getz S.
Apolipoprotein B variant derived from rat intestine.
Proc Natl Acad Sci USA
77:
3806-3810,
1980[Abstract].
18.
Levin, BE.
Glucose increases rat plasma norepinephrine levels by direct action on the brain.
Am J Physiol Regulatory Integrative Comp Physiol
261:
R1351-R1357,
1991
19.
Levin, BE,
and
Sullivan AC.
Glucose, insulin and sympathoadrenal activation.
J Auton Nerv Syst
20:
233-242,
1987[ISI][Medline].
20.
Lewis, GF,
Uffelman KD,
Szeto LW,
and
Steiner G.
Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals.
Diabetes
42:
833-842,
1993[Abstract].
21.
Lewis, GF,
Uffelman KD,
Szeto LW,
Weller B,
and
Steiner G.
Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.
J Clin Invest
95:
158-166,
1995[ISI][Medline].
22.
Lewis, GF,
Zinman B,
Uffelman KD,
Szeto L,
Weller B,
and
Steiner G.
VLDL production is decreased to a similar extent by acute portal vs. peripheral venous insulin.
Am J Physiol Endocrinol Metab
267:
E566-E572,
1994
23.
Malmstrom, R,
Packard CJ,
Caslake M,
Bedford D,
Stewart P,
Yki-Järvinen H,
Shepherd J,
and
Taskinen M-J.
Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects.
Diabetes
47:
779-787,
1998[Abstract].
24.
Malmstrom, R,
Packard CJ,
Caslake M,
Bedford D,
Stewart P,
Yki-Järvinen H,
Shepherd J,
and
Taskinen M-R.
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.
Diabetologia
40:
454-462,
1997[ISI][Medline].
25.
Malmstrom, R,
Packard CJ,
Watson TDG,
Rannikko S,
Caslake M,
Bedford D,
Stewart P,
Yki-Järvinen H,
Shepherd J,
and
Taskinen M-R.
Metabolic basis of hypotriglyceridemic effects of insulin in normal men.
Arterioscler Thromb Vasc Biol
17:
1454-1464,
1997
26.
Markwell, MK,
Haas SM,
Bieber L,
and
Tobert NE.
A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.
Anal Biochem
87:
206-210,
1978[ISI][Medline].
27.
McGowan, MW,
Artiss JD,
Strandergh DR,
and
Zak B.
A peroxidase-coupled method for the colorimetric determination of serum triglycerides.
Clin Chem
29:
538-542,
1983
28.
Orway, S,
and
Robinson DS.
The uses of a non-ionic detergent: (Triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions.
J Physiol (Lond)
190:
321-332,
1967[ISI][Medline].
29.
Palmer, JF,
Cooper C,
and
Shipley RA.
Rate of release of hepatic triacylglycerol in serum in the starved rat.
Biochem J
172:
219-226,
1978[ISI][Medline].
30.
Patsch, W,
Franz S,
and
Schonfeld G.
Role of insulin in lipoprotein secretion by cultured rat hepatocytes.
J Clin Invest
71:
1161-1174,
1983[ISI][Medline].
31.
Patsch, W,
Gotto AM, Jr.,
and
Patsch JR.
Effects of insulin on lipoprotein secretion in rat hepatocyte cultures. The role of the insulin receptor.
J Biol Chem
261:
9603-9606,
1986
32.
Phung, TL,
Roncone A,
De Mesy Jensen KL,
Sparks CE,
and
Sparks JD.
Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein secretion by rat hepatocytes and localizes to the endoplasmic reticulum.
J Biol Chem
272:
30693-30702,
1997
33.
Pullinger, CR,
North JD,
Teng B-B,
Rifici VA,
Ronhild de Brito AE,
and
Scott J.
The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and the measurement of the mRNA half-life.
J Lipid Res
30:
1065-1077,
1989[Abstract].
34.
Reaven, GM.
Pathophysiology of insulin resistance in human disease.
Physiol Rev
75:
473-486,
1995
35.
Saad, MJA,
Araki E,
Miralpeix M,
Rothenberg PL,
White MF,
and
Kahn CR.
Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance.
J Clin Invest
90:
1839-1849,
1992[ISI][Medline].
36.
Shumak, SL,
Zinman B,
Zuniga-Guarjado S,
Poapst M,
and
Steiner G.
Triglyceride-rich lipoprotein metabolism during acute hyperinsulinemia in hypertriglyceridemic humans.
Metabolism
37:
461-466,
1988[ISI][Medline].
37.
Sparks, CE,
and
Marsh JB.
Metabolic heterogeneity of apolipoprotein B in the rat.
J Lipid Res
22:
519-527,
1981[Abstract].
38.
Sparks, CE,
Sparks JD,
Bolognino M,
Salhanick A,
Strumph PS,
and
Amatruda JM.
Insulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytes.
Metabolism
35:
1128-1136,
1986[ISI][Medline].
39.
Sparks, CE,
Tennenberg SD,
and
Marsh JB.
Catabolism of the apolipoproteins of HDL in control and nephrotic rats.
Biochim Biophys Acta
665:
8-12,
1981[ISI][Medline].
40.
Sparks, JD,
Bolognino M,
Trax PA,
and
Sparks CE.
The production and utility of monoclonal antibodies to rat apolipoprotein B lipoproteins.
Atherosclerosis
61:
205-211,
1986[ISI][Medline].
41.
Sparks, JD,
Corsetti JP,
and
Sparks CE.
Liver regrowth and apolipoprotein B secretion by rat hepatocytes following partial hepatectomy.
Metabolism
43:
681-690,
1994[ISI][Medline].
42.
Sparks, JD,
Phung TL,
Bolognino M,
and
Sparks CE.
Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes.
Biochem J
313:
567-574,
1996[ISI][Medline].
43.
Sparks, JD,
and
Sparks CE.
Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes.
J Biol Chem
265:
8854-8862,
1990
44.
Sparks, JD,
and
Sparks CE.
Obese Zucker (fa/fa) rats are resistant to insulin's inhibitory effect on hepatic apoB secretion.
Biochem Biophys Res Commun
205:
417-422,
1994[ISI][Medline].
45.
Sparks, JD,
and
Sparks CE.
Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion.
Biochim Biophys Acta
1215:
9-32,
1994[ISI][Medline].
46.
Sparks, JD,
and
Sparks CE.
Chromatographic method for isolation and quantification of apolipoproteins B-100 and B-48.
Methods Enzymol
263:
104-121,
1996[ISI][Medline].
47.
Sparks, JD,
Sparks CE,
and
Miller LL.
Insulin effects on apolipoprotein B production by normal, diabetic and treated-diabetic rat liver and cultured rat hepatocytes.
Biochem J
261:
83-88,
1989[ISI][Medline].
48.
Stein, DT,
Esser V,
Stevenson BE,
Lane KE,
Whiteside JH,
Daniels MB,
Chen S,
and
McGarry JD.
Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat.
J Clin Invest
97:
2728-2735,
1996
49.
VanHarken, DR,
Dixon CW,
and
Heimberg M.
Hepatic lipid metabolism in experimental diabetes. V. The effect of concentration of oleate on metabolism of triglycerides and on ketogenesis.
J Biol Chem
244:
2278-2285,
1969
50.
Vogelberg, KH,
Gries FA,
and
Moschinski D.
Hepatic production of VLDL-triglycerides. Dependence of portal substrate and insulin concentration.
Horm Metab Res
12:
688-694,
1980[ISI][Medline].
51.
Wang, C-N,
Hobman TC,
and
Brindley DN.
Degradation of apolipoprotein B in cultured rat hepatocytes occurs in a post-endoplasmic reticulum compartment.
J Biol Chem
270:
24924-24931,
1995
52.
Wang, C-N,
McLeod RS,
Yao Z,
and
Brindley DN.
Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes.
Arterioscler Thromb Vasc Biol
15:
1481-1491,
1995
53.
Wiggins, D,
Hems R,
and
Gibbons GF.
Decreased sensitivity to the inhibitory effect of insulin on the secretion of very-low-density lipoprotein in cultured hepatocytes from fructose-fed rats.
Metabolism
44:
841-847,
1995[ISI][Medline].
54.
Yamauchi, T,
Iwai M,
Kobayashi N,
and
Shimazu T.
Noradrenaline and ATP decrease the secretion of triglyceride and apoprotein B from perfused rat liver.
Pflügers Arch
435:
368-374,
1998[ISI][Medline].